ATE323531T1 - Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie - Google Patents

Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie

Info

Publication number
ATE323531T1
ATE323531T1 AT02719751T AT02719751T ATE323531T1 AT E323531 T1 ATE323531 T1 AT E323531T1 AT 02719751 T AT02719751 T AT 02719751T AT 02719751 T AT02719751 T AT 02719751T AT E323531 T1 ATE323531 T1 AT E323531T1
Authority
AT
Austria
Prior art keywords
benigne
receptor antagonists
prostate hyperplasia
antagonists against
hyperplasia
Prior art date
Application number
AT02719751T
Other languages
German (de)
English (en)
Inventor
Susanne Buser
Anthony P D W Ford
Torsten Hoffmann
Barbara Lenz
Andrew John Sleight
Pierre Vankan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE323531T1 publication Critical patent/ATE323531T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02719751T 2001-04-23 2002-02-02 Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie ATE323531T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23

Publications (1)

Publication Number Publication Date
ATE323531T1 true ATE323531T1 (de) 2006-05-15

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02719751T ATE323531T1 (de) 2001-04-23 2002-02-02 Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie

Country Status (17)

Country Link
US (1) US20030004157A1 (OSRAM)
EP (1) EP1385577B1 (OSRAM)
JP (1) JP4146730B2 (OSRAM)
KR (1) KR100599134B1 (OSRAM)
CN (1) CN100398106C (OSRAM)
AR (1) AR035935A1 (OSRAM)
AT (1) ATE323531T1 (OSRAM)
AU (1) AU2002250876B2 (OSRAM)
BR (1) BR0209151A (OSRAM)
CA (1) CA2444395C (OSRAM)
DE (1) DE60210760T2 (OSRAM)
DK (1) DK1385577T3 (OSRAM)
ES (1) ES2261657T3 (OSRAM)
MX (1) MXPA03009720A (OSRAM)
PT (1) PT1385577E (OSRAM)
WO (1) WO2002085458A2 (OSRAM)
ZA (1) ZA200308110B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
CN100562320C (zh) * 2003-01-31 2009-11-25 弗·哈夫曼-拉罗切有限公司 2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
EP1643998B1 (en) * 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
ATE500224T1 (de) 2004-07-06 2011-03-15 Hoffmann La Roche Herstellungsverfahren für carboxamid-pyridin- derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
NZ614151A (en) 2007-12-07 2015-04-24 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2231606B1 (en) 2007-12-07 2013-02-13 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
AU2010225747A1 (en) 2009-03-17 2011-11-10 Daiichi Sankyo Company,Limited Amide derivative
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
JP5806420B1 (ja) 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
CN105848657B (zh) 2013-11-12 2020-05-22 沃泰克斯药物股份有限公司 制备用于治疗cftr介导的疾病的药物组合物的方法
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
SI3221692T1 (sl) 2014-11-18 2021-11-30 Vertex Pharmaceuticals Inc. Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
JP7400180B2 (ja) * 2018-02-02 2023-12-19 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 非経口製剤及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
HUP0003548A3 (en) * 1997-08-06 2002-04-29 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
US6358994B1 (en) * 1997-08-06 2002-03-19 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
DE60014216T2 (de) * 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
MXPA03000366A (es) * 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
CN1503684A (zh) 2004-06-09
CN100398106C (zh) 2008-07-02
EP1385577B1 (en) 2006-04-19
JP4146730B2 (ja) 2008-09-10
DE60210760T2 (de) 2006-11-23
CA2444395A1 (en) 2002-10-31
JP2004529931A (ja) 2004-09-30
DK1385577T3 (da) 2006-08-21
ZA200308110B (en) 2005-03-30
AR035935A1 (es) 2004-07-28
CA2444395C (en) 2010-12-21
ES2261657T3 (es) 2006-11-16
EP1385577A2 (en) 2004-02-04
US20030004157A1 (en) 2003-01-02
BR0209151A (pt) 2004-07-13
PT1385577E (pt) 2006-08-31
DE60210760D1 (de) 2006-05-24
MXPA03009720A (es) 2004-01-29
AU2002250876B2 (en) 2005-03-03
KR20040007503A (ko) 2004-01-24
KR100599134B1 (ko) 2006-07-12
WO2002085458A2 (en) 2002-10-31
WO2002085458A3 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
ATE323531T1 (de) Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
DE60037213D1 (de) Verwendung von Reinigungsgas
DE50212455D1 (de) Verwendung von Dimerdiolen
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE60234167D1 (de) Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60216229D1 (de) Il-8-rezeptorantagonisten
DE02784674T1 (de) Quantifizierung von polypeptiden
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE602004022458D1 (de) Pyrazolderivate und ihre verwendung als orexin-rezeptor-antagonisten
ATE469875T1 (de) Nk1-antagonisten
ATE242002T1 (de) Tumor nekrose faktor antagonisten und ihre verwendung gegen endometriose
ATE374183T1 (de) Nk1-antagonisten
SI1425280T1 (sl) Hetero-biciklicni antagonisti crf
ATE492535T1 (de) 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
ATE356122T1 (de) Pyrazolylsubstituierte heterocyclen und ihre verwendung als schädlingsbekämpfungsmittel
DE60224221D1 (de) Aminotetralinderivate, antagonisten von muscarinrezeptoren
ATE394114T1 (de) Somatostatin-antagonisten
DE60317632D1 (de) 2-oxazolamine und ihre verwendung als 5-ht2b-rezeptor-antagonisten
DE60217870D1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
EE200300335A (et) Histamiiniretseptori antagonistid
ATE370932T1 (de) Ccr-3-rezeptorantagonisten vii
DE60317709D1 (de) Substituierte 1-piperidin-3-yl-4-piperidin-4-yl-piperazin-derivate und ihre verwendung als neurokinin-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1385577

Country of ref document: EP